Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult Japanese Participants With Episodic Migraine (Release)
Migraine
About this trial
This is an interventional treatment trial for Migraine focused on measuring Migraine, Episodic Migraine, Atogepant
Eligibility Criteria
Inclusion Criteria: At least a 1-year history of migraine (with or without aura). Less than 50 years of age at the time of migraine onset. History of 4 to 14 migraine days per month in the 3 months prior to screening. 4 to 14 migraine days in the baseline period and completed at least 20 out of 28 days at the baseline period per the eDiary. Exclusion Criteria: Difficulty with distinguishing migraine headaches from tension-type or other headaches. Clinically significant hematologic, endocrine, pulmonary, renal, hepatic, gastrointestinal, or neurologic disease.
Sites / Locations
- Takanoko Hospital /ID# 245658Recruiting
- Fukuiken Saiseikai Hospital /ID# 245662Recruiting
- Jinnouchi Neurosurgical Clinic /ID# 245510Recruiting
- Ikeda Neurosurgical Clinic /ID# 245881Recruiting
- SUBARU Health Insurance Society Ota Memorial Hospital /ID# 247948Recruiting
- Hiroshima City Hiroshima Citizens Hospital /ID# 246683Recruiting
- Higashi Sapporo Neurology and Neurosurgery Clinic /ID# 245667Recruiting
- Nakamura Memorial Hospital /ID# 247379Recruiting
- Konan Medical Center /ID# 245557Recruiting
- Nishinomiya Municipal Central Hospital /ID# 246571Recruiting
- Yamaguchi Clinic /ID# 246370Recruiting
- Mito Kyodo General Hospital /ID# 245487Recruiting
- Tsukuba Neurosurgery/Headache Clinic /ID# 254665Recruiting
- Kijima Neurosurgery Clinic /ID# 245758Recruiting
- Kanazawa Neurosurgical Hospital /ID# 254210Recruiting
- Tokai University Hospital /ID# 245971Recruiting
- Fujitsu Clinic /ID# 245811Recruiting
- Atago Hospital /ID# 245818Recruiting
- Umenotsuji Clinic /ID# 246103Recruiting
- Saiseikai Kumamoto Hospital /Id# 253546Recruiting
- Narikawa Neurological Clinic /ID# 254023Recruiting
- Sendai Headache and Neurology Clinic Medical Corporation /ID# 245664Recruiting
- Makabe Clinic /ID# 246621Recruiting
- Okayama City General Medical Center /ID# 246007Recruiting
- Gokeikai Osaka Kaisei Hospital /ID# 246623Recruiting
- Chibune General Hospital /ID# 245973Recruiting
- Tominaga Clinic /ID# 245812Recruiting
- Takase Internal Medicine Clinic /ID# 245532Recruiting
- Saitama Medical University Hospital /ID# 245663Recruiting
- Saino Clinic /ID# 245921Recruiting
- Japanese Red Cross Shizuoka Hospital /ID# 246204Recruiting
- Dokkyo Medical University Hospital /ID# 246472Recruiting
- Tokai University Hachioji Hospital /ID# 248326Recruiting
- Kitasato University Kitasato Institute Hospital /ID# 246470Recruiting
- Usuda Clinic Of Internal Medicine /ID# 246166Recruiting
- Tokyo Headache Clinic /ID# 245486Recruiting
- Keio University Hospital /ID# 245660Recruiting
- Suzuki Kei Yasuragi Clinic /ID# 253493Recruiting
- Sakura neuro Clinic /ID# 248320Recruiting
- Nagaseki Headache Clinic /ID# 245485Recruiting
- DOI Internal Medicine-Neurology Clinic /ID# 245661Recruiting
- Tanaka Neurosurgical clinic /ID# 245488Recruiting
- Tatsuoka Neurology Clinic /ID# 245328Recruiting
- Ooba Clinic for Neurosurgery & Headache /ID# 246201Recruiting
- Kokubu Clinic /ID# 245810Recruiting
- Shinagawa Strings Clinic /ID# 245665Recruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Experimental
Experimental
Experimental
Atogepant Dose A
Atogepant Dose B
Atogepant Dose C
Placebo
Participants will receive atogepant dose A once daily (QD) for 24 weeks.
Participants will receive atogepant dose B QD for 24 weeks.
Participants will receive atogepant dose C QD for 24 weeks.
Participants will receive placebo QD for 12 weeks. Participants will be re-randomized at week 12 to receive atogepant dose A, dose B or dose C QD for 12 weeks.